ROC-325
ROC-325 is a potent and orally active autophagy inhibitor with a strong anticancer activity. ROC-325 induces the deacidification of lysosomes, accumulation of autophagosomes, and disrupted autophagic flux. ROC-325 also induces renal cell carcinoma apoptosis[1].
Product Specifications
CAS Number
1859141-26-6
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy
Type
Reference compound
Related Pathways
Apoptosis; Autophagy
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ROC-325.html
Purity
99.45
Solubility
DMSO : 4.55 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL
Smiles
O=C1C2=C(SC3=C1C=CC=C3)C(C)=CC=C2NCCN(CCNC4=CC=NC5=CC(Cl)=CC=C45)C
Molecular Formula
C28H27ClN4OS
Molecular Weight
503.06
Precautions
H302, H315, H319, H335
References & Citations
[1]Carew JS, et al. Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis. Clin Cancer Res. 2017 Jun 1;23 (11) :2869-2879.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC681844-500 1x 500 µL
CD79b (B-Cell Marker) (IGB/1844), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC883350-500 1x 500 µL
NKX3.1 (Metastatic Prostate Adenocarcinoma Marker) (NKX3.1/3350), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC681208-100 1x 100 µL
HLA-DRB (LN-3 + HLA-DRB/1067), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details